Metformin Glipizide Tablets

Metformin hydrochloride and glipizide in metformin hydrochloride glipizide tablets are two widely used and effective oral hypoglycemic drugs. The combination of the two has a synergistic hypoglycemic effect. In addition to reducing the initial dose of the two drugs, it also increases the extensiveness of the drugs, providing a new way for the treatment of diabetes. Glipizide is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of action is to promote endogenous insulin secretion. It takes effect 30 minutes after oral administration and lasts for about 16-24 hours. Metformin hydrochloride is a biguanide oral hypoglycemic drug that reduces blood sugar levels by reducing liver glucose output and increasing peripheral tissue absorption of sugar. It can promote endogenous insulin secretion, reduce fat synthesis, maintain or reduce body weight, and thus reduce the risk factors of arteriosclerosis. The combined use of the two drugs not only enhances the activity of endogenous insulin, but also reduces the occurrence of side effects such as hypoglycemia.

Glipizide 2.5mg/Metformin hydrochloride 250mg

This product is a film-coated tablet, which appears white or off-white after removing the coating.

When using this product alone, it is recommended to combine it with diet and exercise therapy to achieve the effect of controlling blood sugar in non-insulin-dependent (type 2) diabetes. This product can also be used in combination with sulfonylurea hypoglycemic drugs or insulin to control type 2 diabetes.

This product should be dosed individually based on effectiveness and tolerability and should not exceed the maximum recommended dose of 20 mg glipizide and 2000 mg metformin per day. This product should be taken with food and started at a lower dose. The dose should be gradually increased as follows to avoid hypoglycemia, reduce gastrointestinal adverse reactions, and determine the lowest effective dose that can adequately control blood sugar for different patients. Special patient populations Metformin glipizide tablets are not recommended for use during pregnancy or in children. Due to the possibility of reduced renal function, this product should be used with a conservative initial and maintenance dose in elderly patients. Renal function should be assessed before any dose adjustment. In general, the dose should not be increased to the maximum dose in elderly patients, patients who are overly fatigued, or malnourished to avoid the occurrence of

1. Common symptoms include: nausea, vomiting, diarrhea, metallic taste in the mouth. 2. Sometimes there is weakness, tiredness, dizziness, and rash. 3. Although the incidence of lactic acidosis is very low, it should be paid attention to. Clinical manifestations include vomiting, abdominal pain, hyperventilation, mental disorder, and increased lactic acid concentration in the blood that cannot be explained by uremia, ketoacidosis or salicylic acid poisoning. 4. It can reduce the intestinal absorption of vitamin B12, reduce hemoglobin, produce megaloblastic anemia, and also cause malabsorption.

Patients with the following diseases are contraindicated to use metformin hydrochloride: 1. Kidney disease or renal insufficiency caused by cardiovascular failure, acute myocardial infarction and sepsis (such as blood creatinine level ≥1.5mg/dl (male), ≥1.4mg/dl (female) or abnormal creatinine clearance). 2. Congestive heart failure requiring drug treatment, and other serious cardiopulmonary diseases. 3. Patients who have received radiotherapy including parenteral administration of iodinated contrast agents should suspend the use of metformin hydrochloride, because the use of such products can cause acute changes in renal function. 4. Known allergy to metformin hydrochloride and any ingredient in this product. 5. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. 6. Severe

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

This product is a compound preparation of glipizide and metformin hydrochloride. The two drugs improve blood sugar control in patients with type 2 diabetes through complementary mechanisms of action. Glipizide lowers blood sugar by stimulating the release of insulin in the pancreas, and this effect depends on functional beta cells in the pancreatic islets. Extra-pancreatic effects may also play a role in the hypoglycemic mechanism of oral sulfonylureas. The long-term hypoglycemic mechanism of glipizide is not yet fully understood. In the human body, glipizide stimulates insulin secretion through meals. Even with long-term use of glipizide, insulin levels will not increase in the fasting state, but the postprandial insulin response can still be improved after taking the drug for at least 6 months. Metformin hydrochloride can improve glucose tolerance in patients with type 2 diabetes and lower basal blood sugar and postprandial blood sugar. Hydrochloric acid

Keep away from light and store in sealed container.

Each tablet contains 250 mg of metformin hydrochloride and 2.5 mg of glipizide

24 months

Hunan Warrant Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-30

• Address:

  Hunan Liuyang Biomedicine Park

• Tax NO.:

  914301007279773228

• Registered Funds:

  93.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view